Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Thomas T DeLeonDaniel R AlmquistBenjamin R KippBlake T LanglaisAaron R MangoldJennifer L WintersHeidi E KosiorekRichard W JosephRoxana S DroncaMatthew S BlockRobert R McWilliamsLisa A KottschadeKandelaria M RumillaJesse S VossMahesh SeetharamAleksandar SekulicSvetomir N MarkovicAlan H BrycePublished in: PloS one (2020)
Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used.